KR850000528A - 사람의 암을 처치하는 방법 및 암세포에 대한 인터페론 및 암괴사 인자의 효과 - Google Patents

사람의 암을 처치하는 방법 및 암세포에 대한 인터페론 및 암괴사 인자의 효과 Download PDF

Info

Publication number
KR850000528A
KR850000528A KR1019840003763A KR840003763A KR850000528A KR 850000528 A KR850000528 A KR 850000528A KR 1019840003763 A KR1019840003763 A KR 1019840003763A KR 840003763 A KR840003763 A KR 840003763A KR 850000528 A KR850000528 A KR 850000528A
Authority
KR
South Korea
Prior art keywords
htnf
hifn
cells
prepared
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019840003763A
Other languages
English (en)
Korean (ko)
Inventor
제이. 올드(외 4) 일로이드
Original Assignee
제임스 에스. 퀴크
슬로안-케터릴 인스티류트 포어 켄서 리서치
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제임스 에스. 퀴크, 슬로안-케터릴 인스티류트 포어 켄서 리서치 filed Critical 제임스 에스. 퀴크
Publication of KR850000528A publication Critical patent/KR850000528A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1019840003763A 1983-06-27 1984-06-27 사람의 암을 처치하는 방법 및 암세포에 대한 인터페론 및 암괴사 인자의 효과 Ceased KR850000528A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50847283A 1983-06-27 1983-06-27
US508472 1983-06-27

Publications (1)

Publication Number Publication Date
KR850000528A true KR850000528A (ko) 1985-02-27

Family

ID=24022900

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019840003763A Ceased KR850000528A (ko) 1983-06-27 1984-06-27 사람의 암을 처치하는 방법 및 암세포에 대한 인터페론 및 암괴사 인자의 효과

Country Status (15)

Country Link
EP (1) EP0131789A3 (enExample)
JP (1) JPS6036420A (enExample)
KR (1) KR850000528A (enExample)
AU (1) AU587959B2 (enExample)
CA (1) CA1265444A (enExample)
DD (3) DD229713A5 (enExample)
DK (1) DK311984A (enExample)
ES (2) ES533767A0 (enExample)
FI (1) FI842560L (enExample)
GR (1) GR82260B (enExample)
HU (2) HU197358B (enExample)
NO (1) NO842572L (enExample)
NZ (1) NZ208648A (enExample)
PT (1) PT78773B (enExample)
ZA (1) ZA844377B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4920196A (en) * 1982-07-30 1990-04-24 Genentech, Inc. Human lymphotoxin
JPS59141519A (ja) * 1983-01-31 1984-08-14 Otsuka Pharmaceut Co Ltd 制ガン作用を有する蛋白質
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
US4879226A (en) * 1984-04-06 1989-11-07 Asahi Kasei Kogyo Kabushiki Kaisha Novel human physiologically active polypeptide
JPS60243018A (ja) * 1984-05-17 1985-12-03 Yamanouchi Pharmaceut Co Ltd ヒト内来性癌制御因子
DE3423234A1 (de) * 1984-06-23 1986-02-06 Boehringer Ingelheim International GmbH, 6507 Ingelheim Synergistische mischungen von interferonen und tumor-nekrose-faktor
US4650674A (en) * 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
GR851626B (enExample) * 1984-07-05 1985-11-26 Genentech Inc
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US6686455B1 (en) 1984-07-05 2004-02-03 Genentech, Inc. Tumor necrosis factor
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
JP2675294B2 (ja) * 1984-10-15 1997-11-12 カイロン コーポレイション ヒト腫瘍壊死因子
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
WO1986003751A2 (en) * 1984-12-21 1986-07-03 Biogen N.V. Purification, production and use of tumor necrosis factors
EP0205038A1 (en) * 1985-05-29 1986-12-17 Suntory Limited Polypeptide, process for preparing it, microorganism and pharmaceutical use
US4894439A (en) * 1986-05-22 1990-01-16 Cetus Corporation N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes
US4677197A (en) * 1985-10-30 1987-06-30 Cetus Corporation Purification method for tumor necrosis factor
NZ219027A (en) * 1986-01-24 1989-09-27 Genentech Inc Antiviral composition containing interferon tumour necrosis factor and/or lymphotoxin
US4828830A (en) * 1986-01-24 1989-05-09 Genentech, Inc. Method and composition for prophylaxis and treatment of viral infections
US4863727A (en) * 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
US5425940A (en) * 1986-04-09 1995-06-20 Cetus Oncology Corporation Combination therapy using interleukin-2 and tumor necrosis factor
CA1290249C (en) * 1986-04-09 1991-10-08 Cetus Corporation COMBINATION THERAPY USING INTERLEUKIN-2 AND/OR INTERFERON-.beta. AND TUMOR NECROSIS FACTOR
IL80005A (en) * 1986-09-10 1992-11-15 Yeda Res & Dev Compositions for modulating the effect of tnf and il-1
US4894225A (en) * 1987-03-02 1990-01-16 Cetus Corporation Combination therapy using antitumor immunotoxins with tumor necrosis factor
DE102012024749A1 (de) 2012-12-11 2014-06-26 Martin Röcken Tumorprävention und -therapie durch Induktion einer Tumorseneszenz

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8204382L (sv) * 1981-07-21 1983-01-22 Hayashibara Biochem Lab Sett att framstella malcellysfaktor och anvendning derav
JPH0695939B2 (ja) * 1983-12-02 1994-11-30 大日本製薬株式会社 ウサギ癌壊死因子をコ−ドするクロ−ン化ｄνａ
GR851626B (enExample) * 1984-07-05 1985-11-26 Genentech Inc

Also Published As

Publication number Publication date
ES545258A0 (es) 1986-07-16
PT78773A (en) 1984-07-01
ES8603949A1 (es) 1986-01-01
HU197358B (en) 1989-03-28
ES533767A0 (es) 1986-01-01
GR82260B (enExample) 1984-12-13
FI842560A7 (fi) 1984-12-28
DD229713A5 (de) 1985-11-13
ES8608885A1 (es) 1986-07-16
DD241268A5 (de) 1986-12-03
EP0131789A3 (en) 1986-12-03
NZ208648A (en) 1989-07-27
HUT34775A (en) 1985-04-28
AU2933784A (en) 1985-01-03
HU201680B (en) 1990-12-28
AU587959B2 (en) 1989-09-07
ZA844377B (en) 1985-05-29
PT78773B (en) 1986-06-26
FI842560A0 (fi) 1984-06-26
DK311984A (da) 1984-12-28
EP0131789A2 (en) 1985-01-23
JPS6036420A (ja) 1985-02-25
DK311984D0 (da) 1984-06-26
DD241271A5 (de) 1986-12-03
NO842572L (no) 1984-12-28
FI842560L (fi) 1984-12-28
CA1265444A (en) 1990-02-06

Similar Documents

Publication Publication Date Title
Liotta et al. Degradation of basement membrane by murine tumor cells
Bretscher et al. Nutrition of Myxococcus xanthus, a fruiting myxobacterium
US4789658A (en) Immunoprophylactic and immunotherapeutic agents
Fidler In vitro studies of cellular-mediated immunostimulation of tumor growth
CA1224435A (en) Protein having cell growth stimulating action composition thereof and method for producing the same
Shaw et al. Effects of costimulator on immune responses in vitro
JPS6036420A (ja) ヒトのがん細胞に対するヒト腫瘍壊死因子およびヒト・インタ−フエロンの作用および方法
Broxmeyer et al. In vitro regulation of a mouse myelomonocytic leukemia line adapted to culture
EP0132125B2 (en) A protein having antitumor activity
Männel et al. Separation of a serum-derived tumoricidal factor from a helper factor for plaque-forming cells.
US4468460A (en) Method of human cell culture
Wittenberg et al. Folic acid derivatives in the gas gland of Physalia physalis L
Young et al. Long-term primary culture of mouse mammary tumor cells: production of virus
HU215262B (hu) Eljárás módosított bakteriális fehérjekivonat és ezt a kivonatot tartalmazó gyógyszerkészítmény előállítására
Tabata et al. Cutaneous localization of endothelin‐1 in patients with systemic sclerosis: immunoelectron microscopic study
Tunis et al. Studies on the nucleoside phosphotransferase of carrot II. Separation of transferase and phosphatase activities
Tarnowski et al. Influence of genotype of host on regression of solid and ascitic forms of sarcoma 180 and effect of chemotherapy on the solid form
Goddard et al. Phospholipase A2-mediated inflammation induces regression of malignant gliomas
Pollock et al. Long-chain unsaturated fatty acids as essential bacterial growth factors. Substances able to replace oleic acid for the growth of CorynebacteriumQ'with a note on a possible method for their microbiological assay
Kawakami et al. Lymphokine-activated killer cells and aging in mice: significance for defining the precursor cell
Li et al. Relationship between ribosomal activity and age of culture in Escherichia coli B
Spitz Immunoelectrophoretic pattern of phytohaemagglutinin
Rimington et al. Role of mitochondria in the in vitro formation of protoporphyrin and haem
Andrus et al. Interleukin 2 production by alloantigen (H‐2) activated T cells
Yu et al. The sensitivity of ehrlich ascitic carcinoma cells to the emperipolesis of thymus lymphocytes

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19840627

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19890627

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19840627

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19910701

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 19910919

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19910701

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I